小摩:重申阿斯利康“增持”评级,2027年临床数据读出或重塑增长前景

格隆汇
Yesterday
摩根大通重申对阿斯利康的“增持”评级,维持目标价160英镑不变,对应市盈率约19倍。该行预计2027年将有六项第三期临床试验数据读出,这些数据合计提供逾100亿美元的风险调整后峰值销售潜力,有助提升市场对阿斯利康在2030年后持续增长能力的信心。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10